Time to optimize vaccination strategies in blood cancer patients

Ibrahim N. Muhsen; Helen E. Heslop

doi:10.1111/bjh.19598

Time to optimize vaccination strategies in blood cancer patients

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS-CoV2 vaccine in patients with follicular lymphoma receiving front-line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points. Commentary on: Lim et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440-451.

Original language	English (US)
Pages (from-to)	406-408
Number of pages	3
Journal	British Journal of Haematology
Volume	205
Issue number	2
DOIs	https://doi.org/10.1111/bjh.19598
State	Published - Aug 2024

Keywords

SARS-CoV-2 vaccines
follicular lymphoma
immune response

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.19598

Cite this

@article{d6181dc2fa6f41288cd8f1d5779f9a0e,

title = "Time to optimize vaccination strategies in blood cancer patients",

abstract = "Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS-CoV2 vaccine in patients with follicular lymphoma receiving front-line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points. Commentary on: Lim et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440-451.",

keywords = "SARS-CoV-2 vaccines, follicular lymphoma, immune response",

author = "Muhsen, {Ibrahim N.} and Heslop, {Helen E.}",

note = "Publisher Copyright: {\textcopyright} 2024 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = aug,

doi = "10.1111/bjh.19598",

language = "English (US)",

volume = "205",

pages = "406--408",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Time to optimize vaccination strategies in blood cancer patients

AU - Muhsen, Ibrahim N.

AU - Heslop, Helen E.

PY - 2024/8

Y1 - 2024/8

N2 - Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS-CoV2 vaccine in patients with follicular lymphoma receiving front-line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points. Commentary on: Lim et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440-451.

AB - Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS-CoV2 vaccine in patients with follicular lymphoma receiving front-line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points. Commentary on: Lim et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440-451.

KW - SARS-CoV-2 vaccines

KW - follicular lymphoma

KW - immune response

UR - http://www.scopus.com/inward/record.url?scp=85196296927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85196296927&partnerID=8YFLogxK

U2 - 10.1111/bjh.19598

DO - 10.1111/bjh.19598

M3 - Comment/debate

AN - SCOPUS:85196296927

SN - 0007-1048

VL - 205

SP - 406

EP - 408

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Time to optimize vaccination strategies in blood cancer patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this